Unnamed: 0,title,date,stock,sentiment
106583.0,77 Biggest Movers From Yesterday,2020-06-05 05:18:00-04:00,ATNM,neutral
106584.0,60 Stocks Moving In Thursday's Mid-Day Session,2020-06-04 12:26:00-04:00,ATNM,neutral
106585.0,Actinium Pharmaceuticals shares are trading higher after H.C. Wainwright initiated coverage on the company's stock with a Buy rating and announced a $3 price target.,2020-06-04 07:24:00-04:00,ATNM,positive
106586.0,"H.C. Wainwright Initiates Coverage On Actinium Pharmaceuticals with Buy Rating, Announces Price Target of $3",2020-06-04 06:38:00-04:00,ATNM,neutral
106587.0,Sabby Management Llc Reports 7.29% Passive Stake in Actinium Pharmaceuticals as of April 22,2020-05-01 08:47:00-04:00,ATNM,positive
106588.0,70 Biggest Movers From Yesterday,2020-04-23 04:12:00-04:00,ATNM,neutral
106589.0,Mid-Afternoon Market Update: Dow Climbs 450 Points; American Eagle Outfitters Shares Slide,2020-04-22 14:30:00-04:00,ATNM,positive
106590.0,46 Stocks Moving In Wednesday's Mid-Day Session,2020-04-22 12:13:00-04:00,ATNM,neutral
106591.0,Mid-Day Market Update: Crude Oil Jumps 25%; VBI Vaccines Shares Plunge,2020-04-22 12:01:00-04:00,ATNM,negative
106592.0,Mid-Morning Market Update: Markets Open Higher; Kimberly-Clark Beats Q1 Expectations,2020-04-22 10:12:00-04:00,ATNM,neutral
106593.0,"The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership",2020-04-22 07:51:00-04:00,ATNM,negative
106594.0,32 Stocks Moving in Wednesday's Pre-Market Session,2020-04-22 07:16:00-04:00,ATNM,neutral
106595.0,Actinium Pharmaceuticals Prices 183M Share Public Offering @$0.15/Share,2020-04-22 05:43:00-04:00,ATNM,positive
106596.0,"Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering; Terms Not Disclosed",2020-04-21 16:10:00-04:00,ATNM,neutral
106597.0,"Actinium Reports Single Ad Hoc Interim Analysis For SIERRA Trial Will Be Exercised At Co.'s Discretion In Q2'20, Sees Topline Data Results Available In Q4'20",2020-04-16 07:10:00-04:00,ATNM,neutral
106598.0,"Actinium Pharma Reports First Patient Treated In Third, Final Dose Cohort Of Actimab-A CLAG-M Combo Phase 1 Trial In ACute Myeloid Leukemia",2020-03-05 07:40:00-05:00,ATNM,neutral
106599.0,Actinium Announces Actimab-A Plus 7+3 Combination Trial For Newly Diagnosed Acute Myeloid Leukemia Patients,2020-02-26 07:36:00-05:00,ATNM,neutral
106600.0,Actinium Highlights Presentation Of Findings From Mid-Point Analysis Of Pivotal SIERRA Trial Of Iomab-B At 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR,2020-02-21 07:32:00-05:00,ATNM,neutral
106601.0,Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma,2020-01-13 07:12:00-05:00,ATNM,neutral
106602.0,Actinium Pharmaceuticals Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting,2019-12-09 06:23:00-05:00,ATNM,positive
106603.0,Actinium Pharma to Advance Low Dose Iodine-131 As an Alternative to Standard Chemotherapy,2019-12-09 06:22:00-05:00,ATNM,negative
106604.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,ATNM,positive
106605.0,"The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More",2019-12-01 09:30:00-05:00,ATNM,neutral
106606.0,Actinium Pharmaceuticals shares are trading lower. Not seeing any news to justify the price action.,2019-11-18 10:07:00-05:00,ATNM,neutral
106607.0,Actinium Pharmaceuticals To Present New Clinical Findings From SIERRA Trial Supporting The Iomab-ACT Program For Targeted Lymphodepletion For CAR-T And Adoptive Cell Therapies At ASH 2019 Dec. 7-10,2019-11-06 09:07:00-05:00,ATNM,positive
106608.0,Actinium Pharmaceuticals shares are trading higher. Not seeing any news to justify the price action.,2019-10-31 09:22:00-04:00,ATNM,positive
106609.0,46 Biggest Movers From Yesterday,2019-10-29 05:39:00-04:00,ATNM,neutral
106610.0,Mid-Afternoon Market Update: Crude Oil Down Over 1%; Liberty Property Trust Shares Spike Higher,2019-10-28 15:09:00-04:00,ATNM,positive
106611.0,40 Stocks Moving In Monday's Mid-Day Session,2019-10-28 12:55:00-04:00,ATNM,neutral
106612.0,Mid-Day Market Update: Spotify Jumps Following Q3 Earnings; PG&E Shares Plummet,2019-10-28 12:31:00-04:00,ATNM,positive
106613.0,Mid-Morning Market Update: Markets Open Higher; Walgreens Boots Alliance Earnings Beat Estimates,2019-10-28 10:09:00-04:00,ATNM,neutral
106614.0,Actinium Pharmaceuticals shares are trading lower after the company reported results from the pivotal Iomab-B Phase 3 SIERRA trial.,2019-10-28 09:19:00-04:00,ATNM,neutral
106615.0,Actinium Announces 'Positive' Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial,2019-10-28 08:23:00-04:00,ATNM,neutral
106616.0,"The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings",2019-10-27 12:56:00-04:00,ATNM,neutral
106617.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,ATNM,positive
106618.0,Actinium Achieves Fifty Percent Enrollment In Pivotal Phase 3 SIERRA Trial For Iomab-B,2019-07-23 08:10:00-04:00,ATNM,neutral
106619.0,Actinium Pharma Highlights 2 Presentations At Health Physics Society Annual Meeting Show Support For Profile Of Iomab-B For SIERRA Trial Caregivers,2019-07-11 08:06:00-04:00,ATNM,positive
106620.0,Actinium Highlights Presentation Of New Data Demonstrating Effective Lymphodepletion With Lutetium-177 For CAR-T At The 2019 Society Of Nuclear Medicine And Molecular Imaging Annual Meeting,2019-06-25 08:04:00-04:00,ATNM,positive
106621.0,"The Daily Biotech Pulse:  Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA",2019-06-14 08:47:00-04:00,ATNM,neutral
106622.0,The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace,2019-06-01 11:37:00-04:00,ATNM,neutral
106623.0,Actinium Pharma Highlights Abstract Related To Iomab-B To Be Presented At ASCO,2019-05-16 08:05:00-04:00,ATNM,neutral
106624.0,54 Biggest Movers From Thursday,2019-04-22 05:25:00-04:00,ATNM,neutral
106625.0,Mid-Afternoon Market Update: Pier 1 Imports Falls On Downbeat Q4 Results; Mustang Bio Shares Climb,2019-04-18 14:47:00-04:00,ATNM,positive
106626.0,48 Stocks Moving In Thursday's Mid-Day Session,2019-04-18 12:48:00-04:00,ATNM,neutral
106627.0,Mid-Day Market Update: Dow Up Over 100 Points; Actinium Pharmaceuticals Shares Plunge,2019-04-18 12:23:00-04:00,ATNM,positive
106628.0,Sabby Management Reports 8.02% Passive Stake In Actinium Pharmaceuticals,2019-04-18 11:56:00-04:00,ATNM,positive
106629.0,Actinium Pharma shares are trading lower after the company priced a 43M share common stock offering at $0.385 per share.,2019-04-18 09:07:00-04:00,ATNM,positive
106630.0,Actinium Pharmaceuticals Prices 42.86M Share Common Stock Offering At $0.385/Share,2019-04-18 09:04:00-04:00,ATNM,positive
106631.0,31 Stocks Moving In Thursday's Pre-Market Session,2019-04-18 08:40:00-04:00,ATNM,neutral
106632.0,Actinium Pharmaceuticals shares are trading lower after the company reported a proposed common stock offering.,2019-04-17 16:08:00-04:00,ATNM,neutral
106633.0,Actinium Pharmaceuticals Reports Proposed Common Stock OFfering; Size Not Disclosed,2019-04-17 16:02:00-04:00,ATNM,neutral
106634.0,"Actinium Pharma Highlights Presenation Of 2 Oral, 4 Poster Presentations For AWE At Targeted-Alpha-Therapy International Symposium",2019-04-08 08:11:00-04:00,ATNM,neutral
106635.0,"The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial",2019-04-02 07:30:00-04:00,ATNM,neutral
106636.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-30 09:32:00-04:00,ATNM,neutral
106637.0,"Actinium Reports Novel Combo Of Actimab-A, Venetoclax Accepted For Poster Presentation At AACR Meeting",2019-03-20 08:04:00-04:00,ATNM,positive
106638.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,ATNM,neutral
106639.0,"Centers For Medicaid, Medicare Has Proposed Coverage With Evidence Development For CAR-T Therapy, Decision Would Provide Nationwide Consistency In CMS Coverage",2019-02-15 09:01:00-05:00,ATNM,neutral
106640.0,Actinium Offers Update On Patent Portfolio For its Iomab-ACT Next-Generation CAR-T Lymphodepletion Program,2019-02-06 08:13:00-05:00,ATNM,neutral
106641.0,Actinium Initiates Second Dosing Cohort of Novel Combination Trial with Actimab-A and CLAG-M Salvage Regimen at Medical College of Wisconsin,2019-02-04 08:13:00-05:00,ATNM,positive
106642.0,"Actinium Completes First Module of Collaborative Research Program with Astellas, Second Module Initiated",2019-01-17 08:06:00-05:00,ATNM,neutral
106643.0,"Actinium Highlights Post Presentation Of Actimab-A Phase 2 Trial In Older Patients With Unfit AML At ASH, Showed 'Single Agent Activity of the CD33 Antibody Radiation Conjugate'",2018-12-03 08:10:00-05:00,ATNM,positive
106644.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs",2018-12-02 17:51:00-05:00,ATNM,neutral
106645.0,"The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut",2018-10-31 08:20:00-04:00,ATNM,negative
106646.0,"Actinium Reports Launch Of Iomab-ACT Program Offering Its Targeted, Chemo-Free, Lymphodepletion Technology As Universal Solution To CAR-T Product Developers",2018-10-01 08:08:00-04:00,ATNM,positive
106647.0,"Stocks Which Set New 52-Week High Yesterday, September 26th",2018-09-27 09:12:00-04:00,ATNM,neutral
106648.0,Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients,2018-06-28 08:03:00-04:00,ATNM,positive
106649.0,UPDATE: Actinium Pharmaceuticals Says Iomab-b Remains The Only Targeted Conditioning Treatment In Clinical Trials With The Potential To Increase Access To And Improve Outcomes Of Bone Marrow Transplant,2018-06-26 08:09:00-04:00,ATNM,positive
106650.0,Actinium Pharmaceuticals Announces Dosing Of 38th Patient And 25 Percent Enrollment In Iomab-B Pivotal SIERRA Trial,2018-06-26 08:08:00-04:00,ATNM,neutral
106651.0,Actinium Pharma Reports Treatment Of First Patient In Novel Combination Trial Of Actimab-A Plus CLAG-M,2018-06-13 08:02:00-04:00,ATNM,positive
106652.0,Actinium Pharma Reports Collaborative Research Partnership With Astellas,2018-03-28 08:08:00-04:00,ATNM,neutral
106653.0,Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML,2018-03-13 07:30:00-04:00,ATNM,positive
106654.0,Actinium Pharma Expects $15.4M of Proceeds From its Rights Offering,2018-03-05 07:39:00-05:00,ATNM,neutral
106655.0,Actinium Pharma Reports Progress At BMT Tandem Meetings: 'Protocol changes to the control arm of the pivotal Phase 3 trial for Iomab-B well received',2018-02-28 07:36:00-05:00,ATNM,positive
106656.0,38 Biggest Movers From Yesterday,2018-02-27 04:58:00-05:00,ATNM,neutral
106657.0,Mid-Afternoon Market Update: Telaria Falls Following Q4 Results; Achillion Pharmaceuticals Shares Surge,2018-02-26 14:31:00-05:00,ATNM,positive
106658.0,28 Stocks Moving In Monday's Mid-Day Session,2018-02-26 12:25:00-05:00,ATNM,neutral
106659.0,Actinium Pharmaceuticals Prices 50M Unit Offering At Subscription Price Of $0.50/Unit,2018-02-26 09:54:00-05:00,ATNM,neutral
106660.0,Actinium Announces Submission of IND For Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML,2018-02-12 16:26:00-05:00,ATNM,positive
106661.0,"Actinium Pharma Reports Trial To Study Actimab-A In Combo With CLAG-M Fore Relapse, Refractory AML Patients",2018-02-06 07:33:00-05:00,ATNM,positive
106662.0,Actinium Pharma Announces Rights Offering,2018-02-01 16:09:00-05:00,ATNM,neutral
106663.0,Actinium Pharma Reports Acceptance Of Abstract For AACR Highlighting  Superior In Vivo Survival Data for Actinium Labelled Daratumumab Versus Unlabeled Daratumumab,2018-02-01 07:36:00-05:00,ATNM,positive
106664.0,Actinium Pharmaceuticals Issues Company Update and Outlook for 2018,2018-01-25 08:22:00-05:00,ATNM,neutral
106665.0,Actinium Pharmaceuticals Issues Letter to Investors Providing Company Update and Outlook for 2018,2018-01-25 08:11:00-05:00,ATNM,neutral
106666.0,Actinium Pharma Gives an Update From its AWE Program,2017-12-12 07:31:00-05:00,ATNM,neutral
106667.0,Actinium Highlights Data Presented At ASH Showing CD33 Expression In Significant Number of Multiple Myeloma Patients Supporting Rationale For Actimab-M,2017-12-11 16:17:00-05:00,ATNM,positive
106668.0,Actinium Pharma Offers Prelim. Results From Phase 2 Trial For Actimab-A At ASH: '69% Overall Response Rate and 98% median reduction in bone marrow blasts reported with Actimab-A given at 2.0 ÂµCi/kg/fraction as a single agent',2017-12-11 06:32:00-05:00,ATNM,neutral
106669.0,"B. Riley Initiates Coverage On Actinium Pharmaceuticals with Buy Rating, Announces $2.75 Price Target",2017-12-06 09:31:00-05:00,ATNM,neutral
106670.0,Actinium Pharmaceuticals Announces Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations,2017-12-05 07:38:00-05:00,ATNM,neutral
106671.0,Secondary Offering Lockup Expirations Today For Karmada and Actinum Pharma,2017-10-26 09:08:00-04:00,ATNM,neutral
106672.0,Actinium Pharma Reports Activation Of 15th Clinical Trial Site In Phase 3 SIERRA Trial For Iomab-B,2017-10-25 07:42:00-04:00,ATNM,neutral
106673.0,The Week Ahead: Earnings Season Starts In Earnest,2017-10-23 09:00:00-04:00,ATNM,positive
106674.0,"Actinium Pharma Says Expecting Interim Actimab-A Phase 2 Data in 2017, Top Line Data in 1H 2018",2017-10-04 07:33:00-04:00,ATNM,positive
106675.0,"Actinium Pharmaceuticals Says Phase 2 Clinical Trial Is CUrrently Active At 16 Clinical Trail Sites, Surpassing 10 Clinical Sites That Were Planned For The Trial",2017-10-04 07:33:00-04:00,ATNM,positive
106676.0,Mid-Afternoon Market Update: CyberOptics Drops After Q2 Results; Aaron's Shares Surge,2017-07-28 15:08:00-04:00,ATNM,positive
106677.0,20 Biggest Mid-Day Losers For Friday,2017-07-28 13:09:00-04:00,ATNM,negative
106678.0,Mid-Day Market Update: Boston Beer Surges On Earnings Beat; Destination Maternity Shares Slide,2017-07-28 12:11:00-04:00,ATNM,positive
106679.0,"Actinium Prices Offering Of 21.5M Shares At $0.75/Share, Related Warrant",2017-07-28 09:11:00-04:00,ATNM,positive
106680.0,22 Stocks Moving In Friday's Pre-Market Session,2017-07-28 08:07:00-04:00,ATNM,neutral
106681.0,Actinium Pharmaceuticals Says Iomab-B PHase 3 SIERRA Trial Is Accelerating With Number Of Clinical Trial Sites Increasing,2017-06-15 08:32:00-04:00,ATNM,positive
106682.0,Actinium Pharmaceuticals Names Sandesh Seth CEO,2017-06-09 07:30:00-04:00,ATNM,neutral
106683.0,Actinium Pharmaceuticals Granted Orphan Designation from the EMA for Actimab-A,2017-05-24 09:23:00-04:00,ATNM,positive
106684.0,Actinium Pharma Reports Received Clearance from Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B,2017-05-10 07:00:00-04:00,ATNM,neutral
106685.0,"Actinium Gets Regulatory Pathway for EU Approval of Iomab-B, Trial Design and Primary Endpoint Acceptable as Basis for Marketing Authorization Application",2017-03-21 07:07:00-04:00,ATNM,positive
106686.0,Actinium Pharmaceuticals Reports Pipeline Expansion with Initiation of Clinical Trial of Actimab-M in Multiple Myeloma,2017-02-07 08:02:00-05:00,ATNM,neutral
106687.0,Actinium Pharma has Submitted an Application with the European Medicines Agency Seeking Orphan Designation for Actimab-A,2016-12-13 07:21:00-05:00,ATNM,neutral
106688.0,Actinium Highlights Results from Phase 1 Clinical Trial of Actimab-A at ASH 2016,2016-12-05 21:02:00-05:00,ATNM,neutral
106689.0,Actinium Pharma Expects to Report Interim Phase 2 Data by Mid 2017,2016-11-22 07:05:00-05:00,ATNM,neutral
106690.0,Actinium Pharmaceuticals Announces New Hires As Supply Chain Organization Expands To Accommodate Growth,2016-10-26 07:05:00-04:00,ATNM,positive
106691.0,Actinium Pharma Reports Initiation of Pursuit of Scientific Advice for Iomab-B from EMA,2016-10-25 07:07:00-04:00,ATNM,neutral
106692.0,Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Iomab-B,2016-10-18 07:04:00-04:00,ATNM,positive
106693.0,Mid-Afternoon Market Update: Dow Falls Over 200 Points; Catabasis Shares Spike Higher,2016-09-29 14:38:00-04:00,ATNM,positive
106694.0,12 Biggest Mid-Day Losers For Thursday,2016-09-29 13:10:00-04:00,ATNM,negative
106695.0,Mid-Day Market Update:  Crude Oil Rises Over 2%; Intra-Cellular Therapies Shares Slide,2016-09-29 12:25:00-04:00,ATNM,negative
106696.0,Mid-Morning Market Update: Markets Edge Lower; PepsiCo Beats Q3 Expectations,2016-09-29 10:06:00-04:00,ATNM,negative
106697.0,15 Stocks Moving In Thursday's Pre-Market Session,2016-09-29 08:20:00-04:00,ATNM,neutral
106698.0,Actinium Prices 8M Shares At $1.25/Share,2016-09-29 08:16:00-04:00,ATNM,positive
106699.0,Actinium Reports Offering of Common Shares,2016-09-28 16:10:00-04:00,ATNM,positive
106700.0,15 Biggest Mid-Day Losers For Tuesday,2016-09-27 12:58:00-04:00,ATNM,negative
106701.0,Actinium Pharma Shares Down 9% Amid Profit Taking; Stock Up 20+% Since Sept. 21,2016-09-27 11:30:00-04:00,ATNM,positive
106702.0,Actinium Reports Initiation of Phase 2 Trial of Actimab-A in Patients Newly Diagnosed with Acute Myeloid Leukemia Over Age 60,2016-09-27 07:03:00-04:00,ATNM,neutral
106703.0,Benzinga's Top Initiations,2016-08-25 09:29:00-04:00,ATNM,positive
106704.0,"Roth Capital Initiates Coverage on Actinium Pharmaceuticals at Buy, Announces $5.00 PT",2016-08-25 07:28:00-04:00,ATNM,neutral
106705.0,Actinium Pharmaceuticals Issues Mid-Year Letter to Shareholders Providing Update on Company Progress and Anticipated Milestones,2016-08-04 07:10:00-04:00,ATNM,positive
106706.0,Actinium Pharma Announces Successful Meeting With Investigators For Phase 3 Iomab-BSIERRA Trial,2016-07-20 07:08:00-04:00,ATNM,positive
106707.0,Actinium Pharmaceuticals Starts Pivotal Phase 3 SIERRA Trial,2016-06-29 07:04:00-04:00,ATNM,neutral
106708.0,7 Big Pre-Market Gainers,2016-06-01 09:15:00-04:00,ATNM,neutral
106709.0,Actinium Pharmaceuticals Announces Positive Safety and Efficacy Results From Phase 1 Actimab-A Trial in Patients With Newly Diagnosed Acute Myeloid Leukemia,2016-06-01 07:05:00-04:00,ATNM,positive
106710.0,"Actinium Reports Selection of Zevacor Pharma for Clinical Production, Supply of Lomab-B for Pivotal Phase 3 SIERRA Trial",2016-04-12 07:03:00-04:00,ATNM,neutral
106711.0,Actinium Receives Orphan Drug Designation From FDA for Iomab-B in Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients,2016-03-30 09:31:00-04:00,ATNM,neutral
106712.0,Actinium Pharmaceuticals Files Provisional Patent Application Related to Commercial Scale Labeling and Processes for Iomab-B,2016-03-08 08:34:00-05:00,ATNM,neutral
106713.0,Actinium Pharmaceuticals Selects Medpace Inc. as Clinical Research Organization for Pivotal Phase 3 Iomab-B Trial,2016-03-02 08:08:00-05:00,ATNM,neutral
106714.0,"H.C. Wainwright Initiates Coverage on Actinium Pharmaceuticals at Buy, Announces $8.00 PT",2016-02-29 07:14:00-05:00,ATNM,neutral
106715.0,Napodano: Here Is Actinium's Place Among The CAR-T Hype & Radiopharma Busts,2016-01-07 14:11:00-05:00,ATNM,neutral
106716.0,Actinium Pharma Reports Deal with Memorial Sloan Kettering Cancer Center Related to Certain Liquidity Matters,2015-12-24 13:00:00-05:00,ATNM,negative
106717.0,"Actinium Reports Iomab-B IND Has Been Cleared By FDA; Pivotal, Phase 3 Trial to Proceed",2015-12-17 07:00:00-05:00,ATNM,positive
106718.0,Actinium Pharma Reports Trial Results for Actimab-A Presented at ASH,2015-12-08 08:02:00-05:00,ATNM,neutral
106719.0,"Actinium Reports Filing of Orphan Drug App for US of Iomab-B in Treating Refractory, Relapsed AML in Elderly Patients",2015-11-23 08:02:00-05:00,ATNM,positive
106720.0,"Actinium Submits IOMAB-B IND Application to FDA; Pending FDA Acceptance, Co to Initiate Single, Pivotal Phase 3 Clinical Study In Refractory AML Patients Age 55+",2015-11-17 18:04:00-05:00,ATNM,positive
106721.0,"FBR Capital Initiates Coverage on Actinium Pharmaceuticals at Outperform, Announces $12.00 PT",2015-10-15 07:57:00-04:00,ATNM,neutral
106722.0,Morning Market Gainers,2015-08-10 09:45:00-04:00,ATNM,neutral
106723.0,Actinium Letter to Shareholders Outlining Measures to Move Iomab-B and Actimab-A Into Advanced Development,2015-08-05 10:00:00-04:00,ATNM,positive
106724.0,US Stock Futures Edge Higher; Bank of America Earnings In Focus,2015-07-15 07:07:00-04:00,ATNM,neutral
106725.0,Actinium Advances Iomab-B Towards Phase 3 With Pre-IND Meeting Request,2015-07-15 07:01:00-04:00,ATNM,neutral
106726.0,Actinium Reports Filing of Provisional Patent Application for Infusion Administration of Iomab-B,2015-06-24 07:04:00-04:00,ATNM,neutral
106727.0,Actinium Pharmaceuticals Shares Spike Higher on Report by Technology Profits Confidential,2015-06-19 14:07:00-04:00,ATNM,positive
106728.0,Actinium Pharmaceuticals to Issue Aggregate Of 1.9M Shares of Common Stock @$2.60/Share,2015-06-04 14:37:00-04:00,ATNM,positive
106729.0,Actinium Pharmaceuticals Halted; Pending News,2015-06-04 14:30:00-04:00,ATNM,neutral
106730.0,Actinium's Clinical Data Generates Large Interest at 2015 ASCO Annual Meeting,2015-06-04 07:01:00-04:00,ATNM,positive
106731.0,Actinium Offers Clinical Update on Actimab-A Provided at Targeted Alpha Therapy Symposium,2015-05-28 07:21:00-04:00,ATNM,neutral
106732.0,"Actinium Pharmaceuticals Says Provided Clinical Update on Ongoing Phase I/II Study of Actimab-A, Company's Alpha-Emitting Radiolabeled Antibody",2015-05-28 07:15:00-04:00,ATNM,neutral
106733.0,Actinium to Provide Clinical Update on Actimab-A at Upcoming 2015 ASCO Annual Meeting,2015-05-20 07:01:00-04:00,ATNM,neutral
106734.0,"Actinium Doses the Initial Patient in the Fourth, Final Cohort of Its Actimab-A Trial",2015-04-15 07:00:00-04:00,ATNM,neutral
106735.0,UPDATE: 2 Of 3 Actinium Patients Showed Complete Remission During Ongoing Trials,2015-03-18 07:06:00-04:00,ATNM,neutral
106736.0,Actinium Announces New Data From Current Phase 1/2 Trial of Actimab-A Demonstrating Safety and Robust Clinical Efficacy in High Risk Elderly Acute Myeloid Leukemia Patients,2015-03-18 07:05:00-04:00,ATNM,positive
106737.0,Morning Market Losers,2015-02-06 09:56:00-05:00,ATNM,negative
106738.0,Actinium Prices Public Offering of Common Stock and Warrants to Purchase Common Stock,2015-02-06 08:22:00-05:00,ATNM,neutral
106739.0,Actinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock,2015-02-05 17:05:00-05:00,ATNM,neutral
106740.0,Actinium Submits Pre-IND Meeting Request to the U.S. FDA for its Iomab-B Drug Candidate,2015-01-26 07:07:00-05:00,ATNM,neutral
106741.0,Actinium Submits CMC Meeting Request to FDA for Iomab-B to Support IND Filing and Anticipated Commencement of Phase 3 Trial in Mid-2015,2015-01-20 07:04:00-05:00,ATNM,positive
106742.0,Actinium Receives Orphan-Drug Designation For Actimab-A,2014-12-01 07:04:00-05:00,ATNM,neutral
106743.0,Actinium Pharma's AML Treatment Receives Orphan Designation From FDA,2014-11-26 11:05:00-05:00,ATNM,positive
106744.0,Actinium Pharmaceuticals Actimab-A Phase I/II Trial Interim Data Demonstrate Extension of Overall Survival to 9.1 Months in Elderly Secondary Acute Myeloid Leukemia ,2014-11-06 07:02:00-05:00,ATNM,neutral
106745.0,"MLV & Co. Initiates Coverage on Actinium Pharmaceuticals Inc at Buy, Announces $16.00 PT",2014-10-01 05:53:00-04:00,ATNM,neutral
106746.0,Actinium Files Orphan Drug Application for Actimab-A in Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients ,2014-09-03 07:07:00-04:00,ATNM,neutral
106747.0,Actinium Pharmaceuticals Inc Reports Q2 EPS of $0.10,2014-08-12 16:49:00-04:00,ATNM,neutral
106748.0,Benzinga's Top Initiations ,2014-07-22 09:47:00-04:00,ATNM,positive
106749.0,Canaccord Genuity Initiates Actinium Pharmaceuticals At Buy,2014-07-22 07:46:00-04:00,ATNM,neutral
106750.0,"Canaccord Genuity Initiates Coverage on Actinium Pharmaceuticals Inc at Buy, Announces $16.00 PT",2014-07-22 06:40:00-04:00,ATNM,neutral
106751.0,Actinium Pharma Announces Yair Levy of Baylor to Scientific Advisory Board,2014-07-07 17:11:00-04:00,ATNM,neutral
